HK1206282A1 - 抑制劑及其使用方法 - Google Patents

抑制劑及其使用方法

Info

Publication number
HK1206282A1
HK1206282A1 HK15107116.7A HK15107116A HK1206282A1 HK 1206282 A1 HK1206282 A1 HK 1206282A1 HK 15107116 A HK15107116 A HK 15107116A HK 1206282 A1 HK1206282 A1 HK 1206282A1
Authority
HK
Hong Kong
Prior art keywords
tfpi
methods
inhibitors
tfpi inhibitors
use tfpi
Prior art date
Application number
HK15107116.7A
Other languages
English (en)
Inventor
Michael Dockal
Rudolf Hartmann
Friedrich Scheiflinger
Frank Osterkamp
Thomas Polakowski
Ulrich Reineke
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of HK1206282A1 publication Critical patent/HK1206282A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8114—Kunitz type inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15107116.7A 2012-03-21 2015-07-27 抑制劑及其使用方法 HK1206282A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613865P 2012-03-21 2012-03-21
PCT/US2013/024167 WO2013141965A1 (en) 2012-03-21 2013-01-31 Tfpi inhibitors and methods of use

Publications (1)

Publication Number Publication Date
HK1206282A1 true HK1206282A1 (zh) 2016-01-08

Family

ID=47682077

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107116.7A HK1206282A1 (zh) 2012-03-21 2015-07-27 抑制劑及其使用方法

Country Status (17)

Country Link
US (3) US8962563B2 (zh)
EP (1) EP2827883B1 (zh)
JP (2) JP2015514070A (zh)
KR (2) KR102263685B1 (zh)
CN (3) CN104302306B (zh)
AU (2) AU2013235741C1 (zh)
BR (1) BR112014022435B1 (zh)
CA (1) CA2867363C (zh)
DK (1) DK2827883T3 (zh)
ES (1) ES2733958T3 (zh)
HK (1) HK1206282A1 (zh)
HR (1) HRP20191160T1 (zh)
HU (1) HUE046572T2 (zh)
LT (1) LT2827883T (zh)
NZ (3) NZ724133A (zh)
SI (1) SI2827883T1 (zh)
WO (1) WO2013141965A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
CA2939658C (en) 2014-02-28 2022-10-04 Baxalta Incorporated Peptides and methods of use
CN106687482B (zh) * 2014-09-17 2022-01-25 诺和诺德股份有限公司 能够结合组织因子途径抑制剂(1-161)上的两个表位的抗体
EP3455636B1 (en) * 2016-05-13 2023-08-23 The Scripps Research Institute Compositions and methods for anti-thrombotic and hemostatic therapies
CN114341158B (zh) * 2019-07-08 2024-08-06 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途
EP4108676A4 (en) * 2020-02-22 2024-06-05 JCR Pharmaceuticals Co., Ltd. HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE
AU2023232562A1 (en) 2022-03-08 2024-09-05 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system
US20240216504A1 (en) * 2022-12-30 2024-07-04 Dong Kyu Jin Method for preventing or treating of hemathrosis

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5733175A (en) 1980-07-31 1982-02-23 Mitsubishi Electric Corp Transmitter for signal of elevator
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS607193A (ja) 1983-06-25 1985-01-14 古河電気工業株式会社 回路基板用半田付炉
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co ANDC of human tissue factor inhibitor
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5219994A (en) 1988-11-08 1993-06-15 W. Alton Jones Cell Science Center, Inc. Inhibitor of tissue factor activity
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
DK146190D0 (da) 1990-06-15 1990-06-15 Novo Nordisk As Hidtil ukendte forbindelser
US5622988A (en) 1990-06-15 1997-04-22 Novo Nordisk A/S Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time
US5849703A (en) 1990-08-27 1998-12-15 G. D. Searle & Co. Pre-formed anticoagulant heparin/TFPI complexes
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH04252954A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd タンパクの測定方法、試薬及びキット
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
EP0539975A1 (en) 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
JPH067193A (ja) 1991-11-29 1994-01-18 Teijin Ltd モノクローナル抗体
IL104327A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104314A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
IL104324A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
EP0651655A4 (en) 1992-07-24 1996-05-29 Oklahoma Med Res Found REDUCTION OF MICROVASCULAR BLEEDING DURING SURGERY BY BLOCKING PROTEIN C ACTIVATION
JPH06153985A (ja) 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
EP0693924B2 (en) 1993-02-22 2008-04-09 Abraxis BioScience, Inc. Methods for (in vivo) delivery of biologics and compositions useful therefor
WO1995007986A1 (en) 1993-09-14 1995-03-23 Genentech, Inc. Pharmaceutical compositions containing ecotin and homologs thereof
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
ES2229236T3 (es) 1994-01-11 2005-04-16 Dyax Corporation Inhibidores de la plasmina humana derivados de los dominios de kunitz.
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
JP3681206B2 (ja) 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
CA2279345A1 (en) 1997-01-31 1998-08-06 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US20050032690A1 (en) 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
JP2002503701A (ja) 1998-02-18 2002-02-05 ハーバー−ユーシーエルエイ リサーチ アンド エデュケーション インスティテュート 抗菌性ペプチドおよび誘導したメタペプチド
JP2000128803A (ja) 1998-10-19 2000-05-09 Shionogi & Co Ltd ティッシュ・ファクター・パスウェイ・インヒビター−２抗体
JP2003505678A (ja) 1999-07-23 2003-02-12 ザ スクリップス リサーチ インスティテュート 全血の凝固因子活性を測定する方法
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
WO2001035903A2 (en) 1999-11-16 2001-05-25 Kurnick, James, T. Compositions and methods for regulating tumor-associated antigen expression
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
CA2406583A1 (en) 2000-05-10 2001-11-15 Novo Nordisk A/S Pharmaceutical composition comprising a factor viia and a factor xiii
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
DK1282437T3 (da) 2000-05-16 2008-06-30 Genentech Inc Behandling af brusklidelser
AU2002230390A1 (en) 2000-10-05 2002-04-29 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Ixodes scapularis tissue factor pathway inhibitor
US7374782B2 (en) 2000-10-27 2008-05-20 Baxter International Inc. Production of microspheres
JP2004534855A (ja) 2001-07-20 2004-11-18 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよび第ｘｉ因子ポリペプチドを含んでなる医薬組成物
US20030040480A1 (en) 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
US20030064033A1 (en) 2001-08-16 2003-04-03 Brown Larry R. Propellant-based microparticle formulations
US20080026068A1 (en) 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
US20030211075A1 (en) 2001-09-27 2003-11-13 Thorpe Philip E. Combined compositions for tumor vasculature coagulation and treatment
CN1176943C (zh) * 2001-10-08 2004-11-24 复旦大学 新型重组人组织因子途径抑制物活性肽及其制备方法
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
JP2005510513A (ja) 2001-11-09 2005-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびｔａｆｉポリペプチドを含む薬学的組成物
US20050214836A1 (en) 2002-08-30 2005-09-29 Oncotherapy Science, Inc. Method of diagnosing ovarian endometriosis
WO2005029089A2 (en) 2003-09-24 2005-03-31 Oncotherapy Science, Inc. Method of diagnosing ovarian endometriosis using tfpi-2 protein
AU2003265866A1 (en) 2002-09-03 2004-03-29 Vit Lauermann Targeted release
EP1403638A1 (en) 2002-09-25 2004-03-31 Mondobiotech SA Molecular methods for diagnosing interstitial lung diseases
DE602004031589D1 (de) 2003-01-07 2011-04-14 Dyax Corp Kunitz-domäne-bibliothek
EP1620567A1 (en) 2003-04-15 2006-02-01 Hans-Jürgen Thiesen Method for diagnosing rheumatoid arthritis or osteoarthritis
US20050142205A1 (en) 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
US20070092452A1 (en) 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
MXPA06000720A (es) 2003-07-18 2006-08-23 Baxter Int Metodos para fabricacion, usos y composiciones de particulas esfericas pequenas preparadas por separacion de fase controlada.
CA2532874A1 (en) 2003-07-22 2005-02-03 Baxter International Inc. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
EP1664291B1 (en) 2003-09-09 2012-02-29 Novo Nordisk Health Care AG Coagulation factor vii polypeptides
CN101870729A (zh) 2003-09-09 2010-10-27 诺和诺德医疗保健公司 凝固因子ⅶ多肽
BRPI0414849B1 (pt) 2003-09-29 2017-05-16 Hemoteq Ag produto medicinal e método de revestimento biocompatível de produtos medicinais
US20090232866A1 (en) 2003-10-07 2009-09-17 Mariann Pavone-Gyongyosi Oligopeptides as coating material for medical products
US20050181978A1 (en) 2003-11-20 2005-08-18 Rasmus Rojkjaer Therapeutic use of factor XI
KR101320905B1 (ko) 2003-11-20 2013-11-06 사노피 파스퇴르 인크 백일해 독소의 정제방법 및 이에 유용한 펩타이드
TW200529870A (en) 2003-11-20 2005-09-16 Novo Nordisk Healthcare Ag Therapeutic use of factor XI
US20050147689A1 (en) 2003-12-30 2005-07-07 Egilmez Nejat K. Method for inhibiting the growth of gastrointestinal tract tumors
ES2632124T3 (es) 2004-02-28 2017-09-11 Hemoteq Ag Revestimiento biocompatible, método y utilización de superficies médicas
JP2007537205A (ja) 2004-05-11 2007-12-20 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 熱傷外傷の治療のためのＶＩＩａ因子の使用
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
CN103393601A (zh) 2004-05-12 2013-11-20 巴克斯特国际公司 含有蛋白并在高浓度蛋白下显示可注射性的微球体
WO2005115442A1 (en) 2004-05-25 2005-12-08 Novo Nordisk Health Care Ag Use of coagulation factor xiii for treatment of post surgical bleedings
WO2005117912A1 (en) 2004-05-27 2005-12-15 Avigen, Inc. Methods for treating bleeding disorders using sulfated polysaccharides
US20080058255A1 (en) 2004-06-21 2008-03-06 Novo Nordisk Healthcare A/G Glycosylation-Disrupted Factor VII Variants
WO2006008267A2 (en) 2004-07-16 2006-01-26 Novo Nordisk Health Care Ag Methods for optimizing forming viiia-based hemostatic treatment
US20060040896A1 (en) 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
JP4252954B2 (ja) 2004-12-02 2009-04-08 インターナショナル・ビジネス・マシーンズ・コーポレーション 情報処理装置、情報処理装置のパワーマネージメント方法、およびそのためのプログラム
JP5236952B2 (ja) 2005-02-28 2013-07-17 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 改善された特性を有するｆｘｉｉｉバリアント
EP1869082B1 (en) 2005-03-04 2011-04-13 The Board Of Trustees Of The University Of Illinois Coagulation and fibrinolytic cascades modulator
MX2007013356A (es) 2005-04-27 2008-03-26 Baxter Int Microparticulas modificadas en la superficie y metodos de formacion y uso de las mismas.
KR20080008364A (ko) 2005-05-05 2008-01-23 헤모텍 아게 관 스텐트의 전면 코팅
WO2006128497A1 (en) 2005-06-01 2006-12-07 Novo Nordisk A/S Pharmaceutical formulation of factor xi
WO2007014749A2 (en) 2005-07-29 2007-02-08 Universiteit Van Maastricht Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
GB0525999D0 (en) 2005-12-21 2006-02-01 Ares Trading Sa Novel members of the kazal family of serine protease inhibitors
EP1981559B1 (de) 2006-02-09 2016-11-23 B. Braun Melsungen AG Faltenballonbeschichtungsverfahren
US20070192033A1 (en) 2006-02-16 2007-08-16 Microsoft Corporation Molecular interaction predictors
WO2007127834A2 (en) 2006-04-26 2007-11-08 Medtronic, Inc. Compositions and methods of preparation thereof
US20070281031A1 (en) 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
EP1892303A1 (en) 2006-08-22 2008-02-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Methods for identifying therapeutical targets in tumors and for determining and targeting angiogenesis and hemostasis related to adenocarcinomas of the lung
EP1895436A1 (en) 2006-08-31 2008-03-05 Silicos NV Method for evolving molecules and computer program for implementing the same
EP1913962A1 (en) 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
EP2532686B1 (en) 2007-02-23 2018-05-16 Baxalta GmbH Process methods for fucoidan purification from seaweed extracts
EP1972687A1 (en) 2007-03-23 2008-09-24 GenOdyssee Polynucleotides and polypeptides of human factor VII gene, SNPs
WO2008127654A2 (en) 2007-04-11 2008-10-23 The University Of North Carolina At Chapel Hill Methods and compositions for intra-articular coagulation proteins
SG185263A1 (en) 2007-09-28 2012-11-29 Portola Pharm Inc Antidotes for factor xa inhibitors and methods of using the same
WO2009061697A1 (en) 2007-11-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Anticoagulant antagonist and hemophilia procoagulant
WO2009080054A1 (en) 2007-12-21 2009-07-02 Ifxa A/S Protease inhibitor
FR2934052B1 (fr) 2008-07-17 2011-11-25 Stago Diagnostica Dosage de l'activite du facteur tissulaire circulant
UA112050C2 (uk) 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
KR100994996B1 (ko) 2008-08-06 2010-11-18 한국과학기술연구원 페난트렌 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
DK2379096T3 (da) * 2008-12-19 2019-11-25 Baxalta GmbH TFPI-inhibitorer og fremgangsmåder til anvendelse
US8450275B2 (en) 2010-03-19 2013-05-28 Baxter International Inc. TFPI inhibitors and methods of use
US9127088B2 (en) 2010-05-13 2015-09-08 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
HUE042706T2 (hu) * 2011-04-01 2019-07-29 Bayer Healthcare Llc Monoklonális ellenanyagok szövetifaktorút-inhibitor (TFPI) ellen
BR112014016404A8 (pt) 2012-01-23 2017-07-04 N E Chemcat Corp material de alumina, e, catalisador para purificação de gás de exaustão
JP6153985B2 (ja) 2015-10-16 2017-06-28 株式会社スクウェア・エニックス ビデオゲーム処理プログラム、ビデオゲーム処理システム及びビデオゲーム処理方法

Also Published As

Publication number Publication date
CA2867363C (en) 2023-02-28
KR102263685B1 (ko) 2021-06-11
US20170174727A1 (en) 2017-06-22
HRP20191160T1 (hr) 2019-10-04
AU2017221855B2 (en) 2019-08-22
JP7303640B2 (ja) 2023-07-05
KR20200014448A (ko) 2020-02-10
CN104302306B (zh) 2019-03-22
US8962563B2 (en) 2015-02-24
NZ724133A (en) 2020-07-31
KR20140143191A (ko) 2014-12-15
SI2827883T1 (sl) 2019-08-30
WO2013141965A1 (en) 2013-09-26
ES2733958T3 (es) 2019-12-03
CN109134614A (zh) 2019-01-04
US10800816B2 (en) 2020-10-13
BR112014022435A2 (pt) 2017-07-11
NZ629130A (en) 2016-10-28
CA2867363A1 (en) 2013-09-26
US20180155399A1 (en) 2018-06-07
AU2017221855A1 (en) 2017-09-21
BR112014022435B1 (pt) 2023-02-14
DK2827883T3 (da) 2019-07-29
JP2019108360A (ja) 2019-07-04
EP2827883B1 (en) 2019-05-08
LT2827883T (lt) 2019-08-12
NZ749998A (en) 2023-06-30
AU2013235741C1 (en) 2017-12-21
AU2013235741A1 (en) 2014-09-18
US9873720B2 (en) 2018-01-23
EP2827883A1 (en) 2015-01-28
HUE046572T2 (hu) 2020-03-30
US20130252896A1 (en) 2013-09-26
CN104302306A (zh) 2015-01-21
CN109111505A (zh) 2019-01-01
AU2013235741B2 (en) 2017-06-15
JP2015514070A (ja) 2015-05-18

Similar Documents

Publication Publication Date Title
HRP20180953T1 (hr) Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe
HRP20181628T1 (hr) Spojevi i postupci za njihovu upotrebu
HK1208439A1 (zh) -氮雜吲唑化合物及其使用方法
SG11201504022RA (en) Glutamase inhibitors and method of use
HK1205938A1 (zh) 抑制劑及其應用方法
EP2912178A4 (en) SUPER AMPLIFIER AND METHOD FOR USE THEREOF
EP2895083A4 (en) LIGATOR AND METHOD FOR ITS USE
IL227440A0 (en) Spherical support device and methods of use
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
RS58700B1 (sr) Gsk3 inhibitori i postupci njihove primene
HK1207968A1 (zh) 抑制劑及其使用方法
HK1202112A1 (zh) 端錨聚合酶的吡咯並嘧啶酮和吡咯並吡啶酮抑制劑
HK1206282A1 (zh) 抑制劑及其使用方法
EP2852397A4 (en) HUWENTOXIN IV VARIANTS AND METHODS OF USE
ZA201408128B (en) Etract of greyia radlkoferi and use thereof